JP2014529579A - プロドラッグとしてのペンタミジンアミドキシム酸エステルおよびそれらの薬物としての使用 - Google Patents

プロドラッグとしてのペンタミジンアミドキシム酸エステルおよびそれらの薬物としての使用 Download PDF

Info

Publication number
JP2014529579A
JP2014529579A JP2014522041A JP2014522041A JP2014529579A JP 2014529579 A JP2014529579 A JP 2014529579A JP 2014522041 A JP2014522041 A JP 2014522041A JP 2014522041 A JP2014522041 A JP 2014522041A JP 2014529579 A JP2014529579 A JP 2014529579A
Authority
JP
Japan
Prior art keywords
pentamidine
compound according
treatment
bis
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014522041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014529579A5 (enExample
Inventor
クレメント，ベルント
ベルント クレメント，
ジョシュア コットハウス，
ジョシュア コットハウス，
ユルケ コットハウス，
ユルケ コットハウス，
デニス シャーデ，
デニス シャーデ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dritte Patentportfolio Beteiligungs GmbH and Co KG
Original Assignee
Dritte Patentportfolio Beteiligungs GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dritte Patentportfolio Beteiligungs GmbH and Co KG filed Critical Dritte Patentportfolio Beteiligungs GmbH and Co KG
Publication of JP2014529579A publication Critical patent/JP2014529579A/ja
Publication of JP2014529579A5 publication Critical patent/JP2014529579A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014522041A 2011-07-25 2012-07-19 プロドラッグとしてのペンタミジンアミドキシム酸エステルおよびそれらの薬物としての使用 Withdrawn JP2014529579A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11175252.3A EP2550963B1 (de) 2011-07-25 2011-07-25 Pentamidin-Amidoximsäureesters als Prodrugs und ihre Verwendung als Arzneimittel
EP11175252.3 2011-07-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016173855A Division JP2017039727A (ja) 2011-07-25 2016-09-06 プロドラッグとしてのペンタミジンアミドキシム酸エステルおよびそれらの薬物としての使用

Publications (2)

Publication Number Publication Date
JP2014529579A true JP2014529579A (ja) 2014-11-13
JP2014529579A5 JP2014529579A5 (enExample) 2015-09-10

Family

ID=46514404

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014522041A Withdrawn JP2014529579A (ja) 2011-07-25 2012-07-19 プロドラッグとしてのペンタミジンアミドキシム酸エステルおよびそれらの薬物としての使用
JP2016173855A Withdrawn JP2017039727A (ja) 2011-07-25 2016-09-06 プロドラッグとしてのペンタミジンアミドキシム酸エステルおよびそれらの薬物としての使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016173855A Withdrawn JP2017039727A (ja) 2011-07-25 2016-09-06 プロドラッグとしてのペンタミジンアミドキシム酸エステルおよびそれらの薬物としての使用

Country Status (19)

Country Link
US (1) US20130085180A1 (enExample)
EP (1) EP2550963B1 (enExample)
JP (2) JP2014529579A (enExample)
KR (1) KR20140097108A (enExample)
CN (1) CN103874491A (enExample)
AU (1) AU2012288968B2 (enExample)
BR (1) BR112014001787A2 (enExample)
CA (1) CA2842355A1 (enExample)
DK (1) DK2550963T3 (enExample)
ES (1) ES2610652T3 (enExample)
HR (1) HRP20170013T1 (enExample)
HU (1) HUE030245T2 (enExample)
LT (1) LT2550963T (enExample)
PL (1) PL2550963T3 (enExample)
PT (1) PT2550963T (enExample)
RS (1) RS55557B1 (enExample)
RU (1) RU2608388C2 (enExample)
SI (1) SI2550963T1 (enExample)
WO (1) WO2013014059A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022514685A (ja) * 2018-12-20 2022-02-14 オーランサ インコーポレイテッド ペンタミジンの類似体及びその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150126595A (ko) 2012-12-21 2015-11-12 벌릭스 파마 인코포레이티드 간 질환 또는 증상의 치료를 위한 용도 및 방법
EP3687514A4 (en) * 2017-09-27 2021-06-30 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR INHIBITING STAT3
US10835581B2 (en) 2017-11-28 2020-11-17 University of Pittsburgh—of the Commonwealth System of Higher Education Method of treating insulin resistance
WO2024211870A2 (en) * 2023-04-07 2024-10-10 Auransa Inc. Pentamidine analogue polymorphs, formulations, and methods thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000500469A (ja) * 1995-11-16 2000-01-18 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 抗ニューモシスティス属作用物質としてのベンズアミドオキシム系プロドラッグ
JP2011510956A (ja) * 2008-02-01 2011-04-07 ドリッテ パテントポートフォーリオ ベタイリグングスゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト アミドキシムカルボン酸エステル及びｎ−ヒドロキシグアニジンカルボン酸エステルのプロドラッグの製造のための使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4321444A1 (de) * 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000500469A (ja) * 1995-11-16 2000-01-18 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 抗ニューモシスティス属作用物質としてのベンズアミドオキシム系プロドラッグ
JP2011510956A (ja) * 2008-02-01 2011-04-07 ドリッテ パテントポートフォーリオ ベタイリグングスゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト アミドキシムカルボン酸エステル及びｎ−ヒドロキシグアニジンカルボン酸エステルのプロドラッグの製造のための使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6016009017; Ｃｌｅｍｅｎｔ，　Ｂ．　ｅｔ　ａｌ．: 'Ｄｉａｃｅｔｙｌｄｉａｍｉｄｏｘｉｍｅｅｓｔｅｒ　ｏｆ　ｐｅｎｔａｍｉｄｉｎｅ，　ａ　ｐｒｏｄｒｕｇ　ｆｏｒ　ｔｒｅａｔｍｅｎｔ　ｏｆ　ｐｒｏｔｏｚｏａｌ　ｄｉｓｅａｓｅｓ：　ｓｙｎｔｈｅｓｉｓ，　ｉ' ＣｈｅｍＭｅｄＣｈｅｍ １（１１）, 2006, １２６０-１２６７ *
JPN6016009018; Ｓｃｈａｄｅ，　Ｄ．　ｅｔ　ａｌ．: 'Ｔｈｅ　Ｐｅｐｔｉｄｙｌｇｌｙｃｉｎｅ　alpha-Ａｍｉｄａｔｉｎｇ　Ｍｏｎｏｏｘｙｇｅｎａｓｅ　（ＰＡＭ）：　Ａ　Ｎｏｖｅｌ　Ｐｒｏｄｒｕｇ　Ｓｔｒａｔｅｇｙ　ｆｏｒ　Ａｍｉｄｏｘｉｍｅｓ　ａｎｄ　Ｎ-' ＣｈｅｍＭｅｄＣｈｅｍ ４（１０）, 2009, １５９５-１５９９ *
JPN6016009019; Ｋｏｔｔｈａｕｓ，　Ｊ．　ｅｔ　ａｌ．: 'Ｓｙｎｔｈｅｓｉｓ　ａｎｄ　ｂｉｏｌｏｇｉｃａｌ　ｅｖａｌｕａｔｉｏｎ　ｏｆ　Ｌ-ｖａｌｉｎｅ-ａｍｉｄｏｘｉｍｅｅｓｔｅｒｓ　ａｓ　ｄｏｕｂｌｅ　ｐｒｏｄｒｕｇｓ　ｏｆ　ａｍｉｄｉｎｅｓ' Ｂｉｏｏｒｇａｎｉｃ　＆　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ １９（６）, 20110203, １９０７-１９１４ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022514685A (ja) * 2018-12-20 2022-02-14 オーランサ インコーポレイテッド ペンタミジンの類似体及びその使用

Also Published As

Publication number Publication date
CA2842355A1 (en) 2013-01-31
HUE030245T2 (en) 2017-04-28
SI2550963T1 (sl) 2017-05-31
CN103874491A (zh) 2014-06-18
RU2608388C2 (ru) 2017-01-18
RS55557B1 (sr) 2017-05-31
KR20140097108A (ko) 2014-08-06
PL2550963T3 (pl) 2017-08-31
EP2550963B1 (de) 2016-10-12
US20130085180A1 (en) 2013-04-04
RU2014106867A (ru) 2015-08-27
PT2550963T (pt) 2017-01-19
WO2013014059A1 (de) 2013-01-31
BR112014001787A2 (pt) 2017-02-21
EP2550963A1 (de) 2013-01-30
JP2017039727A (ja) 2017-02-23
AU2012288968A1 (en) 2014-02-13
ES2610652T3 (es) 2017-04-28
HRP20170013T1 (hr) 2017-03-10
AU2012288968B2 (en) 2017-01-05
DK2550963T3 (en) 2017-01-30
LT2550963T (lt) 2017-02-27

Similar Documents

Publication Publication Date Title
US12239733B2 (en) Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
JP2017039727A (ja) プロドラッグとしてのペンタミジンアミドキシム酸エステルおよびそれらの薬物としての使用
EA028413B1 (ru) Фармацевтические композиции
US20160250339A1 (en) Pegylated Artesunate Derivative, Pharmaceutical Composition and Use Thereof
CN116367837A (zh) 抗病毒化合物的制剂
RU2236852C1 (ru) Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций
JP2021503441A (ja) Ｐｅｇ化されたカルフィルゾミブ化合物の安定組成物
JP2014521619A (ja) プロドラッグとしてのダビガトラン−アミドキシム酸エステル類および医薬品としてのそれらの使用
CN109417016B (zh) 用于治疗缺血-再灌注损伤的戊二酸化合物
CN105934243A (zh) 治疗肝病症的方法
EA008594B1 (ru) 2-аминобензотиазолсульфонамидные ингибиторы протеазы вич широкого спектра действия
US9662308B2 (en) Orally bioavailable pentamidine prodrugs for the treatment of diseases
CN103880797B (zh) 苯并呋喃类化合物及其医药用途
CN116650490B (zh) 化合物mt-1207在降低尿酸方面的应用
US20260014072A1 (en) Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
WO2020081723A1 (en) Carbon monoxide prodrugs for the treatment of medical disorders
JP6959049B2 (ja) 新規低アルブミン血症改善薬
CN119613310A (zh) 一种伊洛前列素衍生物及其制备方法和应用
HK1217300B (en) Treatment of oculopharyngeal muscular dystrophy by intravenous administration of trehalose

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150717

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160808

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161019